DDrare: Database of Drug Development for Rare Diseases

Carbamazepine (DrugBank: Carbamazepine)

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
231	Alpha-1-antitrypsin deficiency	1

13. Multiple sclerosis/Neuromyelitis optica [ 3,050 clinical trials, 2,147 drugs, (DrugBank: 348 drugs), 244 drug target genes, 228 drug target pathways]

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 3,050 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04371575 (ClinicalTrials.gov)	September 1, 2012	29/4/2020	Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients	Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - Clinical Characteristics, Neuroanatomical Abnormalities and Treatment Efficacy	Trigeminal Neuralgia;Multiple Sclerosis;Pain, Neuropathic	Drug: Carbamazepine	Stine Maarbjerg, MD PhD	NULL	Completed	N/A	N/A	All	60		NULL

231. Alpha-1-antitrypsin deficiency [ 83 clinical trials, 89 drugs, (DrugBank: 16 drugs), 35 drug target genes, 46 drug target pathways]

Searched query = "Alpha-1-antitrypsin deficiency", "AATD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

1 / 83 trial found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01379469 (ClinicalTrials.gov)	January 2012	15/6/2011	Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency	A Preliminary Study of the Efficacy and Safety of Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency	Alpha-1-antitrypsin Deficiency;Liver Cirrhosis	Drug: Drug-Carbamazepine (Tegretol XR);Drug: Carbamazepine (Tegretol XR) Placebo	Washington University School of Medicine	Novartis;National Institutes of Health (NIH);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);University of Pittsburgh	Recruiting	14 Years	80 Years	All	30	Phase 2	United States